NASDAQ:MOR MorphoSys Q2 2024 Earnings Results & Report $18.96 0.00 (0.00%) As of 10/9/2026 MorphoSys was expected to report Q2 2024 earnings on August 29, 2024, after market closes. Analysts expected earnings of -$0.50 per share. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:Profile Earnings Announcement Details QuarterQ2 2024Announcement DateAugust 29, 2024TimeAfter Market ClosesConference Call4:00 PM ET MorphoSys EPS ResultsActual EPSN/AConsensus EPS -$0.50Beat/MissN/AOne Year Ago EPS-$0.59EPS Beat Rate2 of last 5 quartersMorphoSys Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesInterim ReportCompany ProfilePowered by Earnings DocumentsInterim report MorphoSys Earnings HeadlinesMorphosys AG : MORMay 31, 2026 | 247wallst.comNovartis notches another win for drug acquired in MorphoSys dealDecember 9, 2025 | finance.yahoo.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 10 at 1:00 AM | Altimetry (Ad)Novartis' Avidity Deal: Growth Accretive, Multiple Gated By ExecutionOctober 27, 2025 | seekingalpha.comMyelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...October 7, 2025 | theglobeandmail.comMaxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comSee More MorphoSys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MorphoSys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MorphoSys and other key companies, straight to your email. Email Address About MorphoSysMorphoSys (NASDAQ:MOR) was a German biopharmaceutical company focused on discovering, developing and commercializing innovative antibody-based medicines for serious diseases, particularly cancer and autoimmune disorders. The company built its research programs around antibody technologies and developed products both independently and through collaborations with larger pharmaceutical companies. MorphoSys’s principal marketed products included Monjuvi in the United States and Minjuvi in Europe, an antibody therapy for certain adults with relapsed or refractory diffuse large B-cell lymphoma, developed in partnership with Incyte. Its earlier antibody discovery work also contributed to Tremfya, a treatment for inflammatory diseases developed and commercialized with Janssen Biotech. MorphoSys additionally advanced investigational medicines, including pelabresib, a therapy studied for myelofibrosis. Founded in 1992 and headquartered near Munich, Germany, MorphoSys served international markets through its own commercial operations and pharmaceutical partnerships. Jean-Paul Kress served as the company’s chief executive officer during its final years as an independent business. Novartis acquired MorphoSys in 2024, and the company subsequently ceased operating as an independent publicly traded entity.View MorphoSys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
